Investor Presentation
23
Investor presentation
First six months of 2022
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Novo NordiskⓇ
Diabetes care
DKK
billion
1000
DKK
billion
Obesity care
#1
50%
24
20
Haemophilia
DKK
billion
#1
100
80%
80
#3
50%
40%
800
40%
16
60%
60
600
30%
60
30%
12
40%
400
20%
40
40
20%
8
200
CAGR¹ value: 11.28%
10%
CAGR² value: 44.4%
20% 20
10%
4
CAGR³ value: 3.8%
0
0%
0
0% 0
0%
May
2017
May
2022
May
2020
May
2022
FY
FY
2018
2021
Market value
Market value
Market value
NN value market share (RHS)
Global market position
NN value market share (RHS)
Global market position
NN value market share (RHS)
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 4-year period; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, Recombinant and plasma derived products;
Source: Company reports for haemophilia market; IQVIA MAT, May 2022; Note: Diabetes and Obesity care market values are based on list prices in the US.
NN: Novo Nordisk.View entire presentation